{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T10:13:08Z","timestamp":1772705588445,"version":"3.50.1"},"reference-count":49,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2014,12,27]],"date-time":"2014-12-27T00:00:00Z","timestamp":1419638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100001755","name":"Mesothelioma Applied Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001755","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012166","name":"National Basic Research Program of China","doi-asserted-by":"crossref","award":["2010CB529401"],"award-info":[{"award-number":["2010CB529401"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81072205"],"award-info":[{"award-number":["81072205"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NCI","award":["CA-114047"],"award-info":[{"award-number":["CA-114047"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2015,7,15]]},"abstract":"<jats:p>Malignant mesothelioma (MM) is a highly invasive and chemoresistant malignancy induced by asbestos fibers. NK4, a hepatocyte growth factor antagonist and angiogenesis inhibitor, consists of the N\u2010terminal hairpin domain and four kringle domains of the \u03b1\u2010chain of hepatocyte growth factor. The therapeutic potential of NK4 has been demonstrated in a variety of tumor types. However, the mechanisms by which NK4 inhibits tumor growth have not been well delineated. In this study, it is shown that the NK4 adenovirus (Ad\u2010NK4) potently inhibits cell viability, invasiveness and tumorigenicity of human MM cells. Significantly, this study demonstrates for the first time that Ad\u2010NK4 inhibits cancer stem\u2010like cell (CSC) properties as assessed by spheroid formation assay, side population analysis and flow cytometric sorting of CD24 cells. In addition to inhibiting phosphorylation of Met and AKT, Ad\u2010NK4 markedly suppressed the active form of \u03b2\u2010catenin, a key mediator of both Wnt and AKT pathways. It is further demonstrated that expression of NK4 suppresses \u03b2\u2010catenin nuclear localization and transcriptional activity. Intriguingly, the expression levels of Oct4 and Myc, two critical stem cell factors and downstream targets of \u03b2\u2010catenin, were also diminished by Ad\u2010NK4. Furthermore, the strong antitumor effect of NK4 was found to be linked to its ability to inhibit CSCs as revealed by immunohistochemical examination of tumor specimens from a mouse xenograft model of human MM. These findings suggest that NK4 acts as a CSC inhibitor by impeding Met\/AKT\/\u03b2\u2010catenin signaling and holds promise for achieving durable therapeutic responses in MM by constraining the CSC component of these aggressive tumors.<\/jats:p>","DOI":"10.1002\/ijc.29391","type":"journal-article","created":{"date-parts":[[2014,12,11]],"date-time":"2014-12-11T08:49:16Z","timestamp":1418287756000},"page":"481-490","source":"Crossref","is-referenced-by-count":14,"title":["Inhibition of mesothelioma cancer stem\u2010like cells with adenovirus\u2010mediated <scp>NK<\/scp>4 gene therapy"],"prefix":"10.1002","volume":"137","author":[{"given":"Xu\u2010Bin","family":"Deng","sequence":"first","affiliation":[{"name":"Cancer Institute, Southern Medical University Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Xiao","sequence":"additional","affiliation":[{"name":"Cancer Biology Program, Fox Chase Cancer Center Philadelphia PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Wu","sequence":"additional","affiliation":[{"name":"Cancer Institute, Southern Medical University Guangzhou China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Jin","sequence":"additional","affiliation":[{"name":"Cancer Biology Program, Fox Chase Cancer Center Philadelphia PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brooke","family":"Mossman","sequence":"additional","affiliation":[{"name":"Department of Pathology University of Vermont College of Medicine Burlington VT"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph R.","family":"Testa","sequence":"additional","affiliation":[{"name":"Cancer Biology Program, Fox Chase Cancer Center Philadelphia PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang\u2010Hui","family":"Xiao","sequence":"additional","affiliation":[{"name":"Cancer Institute, Southern Medical University Guangzhou China"},{"name":"Cancer Biology Program, Fox Chase Cancer Center Philadelphia PA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,12,27]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.10358"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2004.09.044"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2005.05.131"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(97)01475-0"},{"key":"e_1_2_6_6_1","first-page":"6737","article-title":"HGF\/NK4, a four\u2010kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice","volume":"60","author":"Kuba K","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_6_7_1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00125-002-0954-y","article-title":"HGF\/NK4 inhibited VEGF\u2010induced angiogenesis in in vitro cultured endothelial cells and in vivo rabbit model","volume":"46","author":"Nakabayashi M","year":"2003","journal-title":"Diabetologia"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.025148"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.2174\/1871520611009010036"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2004.04.001"},{"key":"e_1_2_6_11_1","doi-asserted-by":"crossref","unstructured":"BuenoR.Multimodality treatments in the management of malignant pleural mesothelioma: an update.Hematol Oncol Clin North Am2005;19:1089\u201397 vii.","DOI":"10.1016\/j.hoc.2005.09.011"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208744"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.176"},{"key":"e_1_2_6_14_1","first-page":"4376","article-title":"Chemotaxis and haptotaxis of human malignant mesothelioma cells: effects of fibronectin, laminin, type IV collagen, and an autocrine motility factor\u2010like substance","volume":"53","author":"Klominek J","year":"1993","journal-title":"Cancer Res"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1445"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/35102167"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-3126"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0909-1010"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1016912108"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.158"},{"key":"e_1_2_6_21_1","first-page":"4349","article-title":"Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma","volume":"53","author":"Taguchi T","year":"1993","journal-title":"Cancer Res"},{"key":"e_1_2_6_22_1","first-page":"3199","article-title":"Characterization of a human malignant mesothelioma cell line (H\u2010MESO\u20101): a biphasic solid and ascitic tumor model","volume":"47","author":"Reale FR","year":"1987","journal-title":"Cancer Res"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.5.2509"},{"key":"e_1_2_6_24_1","first-page":"589","article-title":"AKT activation up\u2010regulates insulin\u2010like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells","volume":"61","author":"Tanno S","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209587"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1061803"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.98.1.247"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1075"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1843.2005.00714.x"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0b013e328302851d"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2010.12.054"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0626"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng1928"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature06835"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.10.12.1443"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25197"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.200800156"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0905016106"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0026753"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceb.2007.02.007"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.11.019"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1151526"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2005.08.020"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature05284"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/stem.29"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.281.5382.1509"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2010.12.010"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2008.05.116"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209470"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-2081"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.29391","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.29391","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:08:30Z","timestamp":1696464510000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.29391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,27]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,7,15]]}},"alternative-id":["10.1002\/ijc.29391"],"URL":"https:\/\/doi.org\/10.1002\/ijc.29391","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,27]]}}}